How big is the enbrel market today, and what are its future growth expectations?
The enbrel market size has grown strongly in recent years. It will grow from $15,876.25 million in 2024 to $16,825.42 million in 2025 at a compound annual growth rate (CAGR) of 6.0%. The growth in the historic period can be attributed to increasing prevalence of rheumatoid arthritis, increasing need for personalized treatments in autoimmune diseases, increasing demand for advanced biologic treatments, increasing healthcare investments in biologics, aging population.
The enbrel market size is expected to see strong growth in the next few years. It will grow to $20,930.93 million in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to growing use of enbrel in multiple indications, increasing government support for biologics and rheumatoid arthritis (ra) treatment, growing awareness of autoimmune diseases, rising awareness of inflammatory diseases in the general population, increasing availability of biosimilars, promoting awareness of enbrel. Major trends in the forecast period include digital healthcare tools for managing autoimmune diseases, global partnerships between pharmaceutical companies, development of long-acting injectable formulations for better patient compliance, integration of artificial intelligence in drug development for autoimmune diseases, development of alternative delivery systems for biologic drugs.
Get Your Free Sample of The Global Enbrel Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20451&type=smp
What have been the primary factors driving the enbrel market’s growth?
The surging prevalence of autoimmune conditions is expected to drive the growth of the enbrel market going forward. Autoimmune conditions occur when the immune system mistakenly attacks the body’s healthy cells and tissues, leading to inflammation and damage in various organs. The increasing prevalence of autoimmune conditions is attributed to factors such as genetic predisposition, environmental triggers, and changes in lifestyle and immune system behavior. The surging prevalence of autoimmune conditions drives the demand for treatments such as Enbrel, which helps manage inflammatory diseases such as rheumatoid arthritis and psoriatic arthritis. For instance, in August 2022, according to the National Library of Medicine, a US-based medical library, in 2022, around 928 cases of autoimmune conditions associated with COVID-19 vaccination. Of these, 81.5% (756 cases) were new-onset autoimmune diseases, with symptoms usually emerging eight days post-vaccination. Women (53.6%) were most affected, with a median age of 48. Therefore, the surging prevalence of autoimmune conditions will drive the enbrel market.
What are the key segments within the enbrel market?
The enbrel market covered in this report is segmented –
1) By Product: Injectable Solution; Prefilled Syringes; Combination Therapy; Extended Release Formulations; Biosimilars
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) By Application: Rheumatoid Arthritis; Juvenile Idiopathic Arthritis; Psoriatic Arthritis; Ankylosing Spondylitis; Other Applications
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/enbrel-global-market-report
Which key players are shaping the enbrel market?
Major companies operating in the enbrel market are Amgen Inc.
How will emerging trends drive the enbrel market throughout the forecast period?
The key trend in the enbrel market is obtaining drug approval by authorities to gain a competitive edge in the industry. Drug approval is the process by which regulatory authorities evaluate and authorize a new drug for sale and use, ensuring its safety, efficacy, and quality based on clinical trial data. For instance, in October 2023, Amgen Inc., a US-based biopharmaceutical company, announced the U.S. Food and Drug Administration (FDA) approval for Enbrel to manage children aged two and up who have active juvenile psoriatic arthritis (JPsA). The approval highlights the unique feature of etanercept as a tumor necrosis factor blocker, demonstrated through comprehensive safety and efficacy studies in adults with psoriatic arthritis (PsA), rheumatoid arthritis (RA), and psoriasis. It also includes pharmacokinetic (PK) data supporting its use in pediatric patients with active juvenile idiopathic arthritis (JIA) and psoriasis. The recommended juvenile PsA (JPsA) dosage is tailored to body weight and administered via weekly subcutaneous injection.
How do regional factors impact the enbrel market, and which region is the largest contributor?
North America was the largest region in the enbrel market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the enbrel market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Enbrel Market Report 2025 Offer?
The enbrel market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Enbrel (generic name: etanercept) is a prescription medication used to treat various autoimmune diseases by suppressing the immune system. It is a biological drug that works by inhibiting tumor necrosis factor (TNF), which causes inflammation in conditions such as rheumatoid arthritis and psoriasis.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20451
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
